$55.8M
+$55.8M this year1 filing since 2026 · latest Equity filed
Contraline is a clinical-stage biotechnology company in Charlottesville, Virginia developing long-lasting, reversible contraceptives for men. Its lead device, ADAM, is a hydrogel implant placed in the vas deferens that blocks sperm while remaining non-hormonal and non-permanent. It is also advancing NES/T, a daily topical hormonal gel obtained through an option-to-license agreement with the Population Council. The company was founded in 2015 out of the University of Virginia and announced a $92.5 million Series B in June 2026, co-led by BVF Partners and RA Capital Management, bringing total funding to roughly $127 million.
What sets it apart
One of the only companies to carry a long-acting, non-hormonal, reversible male contraceptive into human clinical trials, addressing a category where the only established options are condoms and vasectomy.
An investigational implantable male contraceptive: an ultrasound-visible polymer is injected into the vas deferens where it forms a hydrogel acting as a semi-permeable membrane, blocking sperm while allowing fluid to pass.
